The newest tool accepted into ISTAND comes from Deliberate AI<\/a>. The AI-generated Clinical Outcome Assessment\u2014AI-COA for short\u2014uses multimodal behavioral signal processing and machine learning technology to record mental health symptoms and assess the severity of cases of anxiety and depression.<\/p>\n<\/div> \u201cThis marks a pioneering step for the ISTAND program as the first artificial intelligence-based, digital health technology project in neuroscience to be accepted into the pilot program,\u201d Peter Stein, M.D., director of the Office of New Drugs within the FDA\u2019s Center for Drug Evaluation and Research, said in an agency announcement<\/a> this week. \u201cOur acceptance aligns with FDA’s vision of optimizing drug development and evaluation, potentially expediting the availability of safe and effective treatments.\u201d<\/p>\n\n\n\n Resources<\/p>\n\n\n\n FDA Announcement<\/a> and Links to more info.<\/p>\n\n\n\n Deliberate AI<\/a><\/p>\n\n\n\n ISTAND program<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" The FDA began accepting submissions in 2022 for a program to provide support for unconventional drug development tools that can assist, enhance and expedite new drug research. Finally in January 2024, it has accepted its first artificial intelligence-powered tool. The program called Innovative Science and Technology Approaches for New Drugs (ISTAND) pilot is designed to … Continue reading FDA Accepts First AI Drug Development Tool<\/span> ![\"\"](\"https:\/\/i0.wp.com\/tecpsych.com\/techpsych\/wp-content\/uploads\/2024\/01\/brain-ai-1.jpeg?resize=259%2C194&ssl=1\")
<\/figure><\/div>\n\n\n\n